Table 3.
Mutational status and patients’ cutaneous melanoma features. Underlined p highlights statistically significant results (p < 0.05).
| Characteristics | BRAF Mutated | NRAS Mutated | No Mutated | Total | p Value |
p Value BRAF Mut vs. No Mutated |
p Value NRAS Mut vs. No Mutated |
p Value BRAF Mut vs. NRAS Mut |
|
|---|---|---|---|---|---|---|---|---|---|
|
n = 96 (33.5%) |
n = 67 (23.3%) |
n = 124 (43.2%) |
n = 287 (100%) |
||||||
| Environmental characteristics | |||||||||
| Geographic areas | BZ | 33 of 96 (34.4%) |
30 of 67 (44.8%) |
43 of 124 (34.7%) |
106 of 287 (37%) |
0.2 ‡ | 0.2 ‡ | 0.3 ‡ | 0.4 ‡ |
| TS | 45 of 96 (46.9%) |
24 of 67 (35.8%) |
46 of 124 (37.1%) |
115 of 287 (40%) |
|||||
| I/IL | 18 of 96 (18.8%) |
13 of 67 (19.4%) |
35 of 124 (28.2%) |
66 of 287 (23%) |
|||||
| Altitude of residence | Mean (range) |
449.4 (13–1718) |
593 (46–2153) |
509 (10–2131) |
660 (10–2153) |
0.1 † | 0.4 †† | 0.3 †† | 0.1 †† |
| ≤300 m | 52 of 95 (54.7%) |
32 of 67 (47.8%) |
60 of 124 (48.4%) |
144 of 286 (50.3%) |
0.4 ‡ | 0.4 ‡ | 0.3 ‡ | 0.6 ‡ | |
| 300 < m <750 | 19 of 95 (20%) |
13 of 67 (19.4%) |
34 of 124 (27.4%) |
66 of 286 (23%) |
|||||
| ≥750 m | 24 of 95 (25.3%) |
22 of 67 (32.8%) |
30 of 124 (24.2%) |
76 of 286 (26.6%) |
|||||
| Demographic characteristics | |||||||||
| Gender | Male | 63 of 96 (65.6%) |
32 of 67 (47.8%) |
64 of 124 (51.6%) |
159 of 287 (55.4%) |
0.04 ‡ | 0.04 ‡ | 0.6 ‡ | 0.02 ‡ |
| Female | 33 of 96 (34.4%) |
35 of 67 (52.2%) |
60 of 124 (48.4%) |
128 of 287 (44.6%) |
|||||
| Mean age | Years (range) |
62 (16–95) |
73 (32–101) |
71 (21–101) |
71 (16–101) |
0.0001 † | 0.0005 †† | 0.5 †† | 0.0001 †† |
| Pathological characteristics | |||||||||
| Localization § | Head&Neck&Face a | 20 of 96 (20.8%) |
11 of 67 (16.4%) |
38 of 124 (30.6%) |
69 of 287 (24%) |
0.02 ‡ | 0.02 ‡ | 0.1 ‡ | 0.08 ‡ |
| Trunk b | 43 of 96 (44.8%) |
21 of 67 (31.3%) |
33 of 124 (26.6%) |
97 of 287 (33.8%) |
|||||
| Upper Limb c | 8 of 96 (8.3%) |
13 of 67 (19.4%) |
19 of 124 (15.3%) |
40 of 287 (14%) |
|||||
| Lower Limb d | 25 of 96 (26%) |
22 of 67 (32.8%) |
29 of 124 (23.4%) |
76 of 287 (26.5%) |
|||||
| Other sites e | 0 of 96 (0%) |
0 of 67 (0%) |
5 of 124 (4%) |
5 of 287 (1.7%) |
|||||
| Stage | I B | 17 of 96 (17.7%) |
2 of 67 (3%) |
8 of 124 (6.5%) |
27 of 287 (9.4%) |
0.005 ‡ | 0.005 ‡ | 0.2 ‡ | 0.04 ‡ |
| II | 51 of 96 (53.1%) |
43 of 67 (64.2%) |
88 of 124 (71%) |
182 of 287 (63.4%) |
|||||
| III | 23 of 96 (24%) |
15 of 67 (22.4%) |
15 of 124 (12.1%) |
53 of 287 (18.5%) |
|||||
| IV | 5 of 96 (5.2%) |
3 of 67 (4.5%) |
7 of 124 (5.6%) |
15 of 287 (5.2%) |
|||||
| unknown | 0 of 96 (0%) |
4 of 67 (6%) |
6 of 124 (4.8%) |
10 of 287 (3.5%) |
|||||
| Lymph nodes | Positive | 25 of 96 (26%) |
14 of 67 (20.9%) |
16 of 124 (12.9%) |
55 of 287 (19.2%) |
0.07 ‡ | 0.02 ‡ | 0.1 ‡ | 0.5 ‡ |
| Negative | 71 of 96 (74%) |
50 of 67 (74.6%) |
101 of 124 (81.5%) |
222 of 287 (77.4%) |
|||||
| unknown | 0 of 96 (0%) |
3 of 67 (4.5%) |
7 of 124 (5.6%) |
10 of 287 (3.5%) |
|||||
| Breslow’s thickness | Median in mm (range) | 3.2 (1.8−15) |
3.6 (1.9−30) |
3.5 (1.8−22) |
4 (1.8−30) |
0.1 † | 0.3†† | 0.2†† | 0.07 †† |
| Ulceration status | yes | 45 of 96 (47%) |
31 of 67 (46.3%) |
57 of 124 (46%) |
133 of 287 (46.3%) |
0.9 ‡ | 0.7 ‡ | 0.9 ‡ | 0.8 ‡ |
| no | 49 of 96 (51%) |
32 of 67 (47.8%) |
57 of 124 (46%) |
138 of 287 (48.1%) |
|||||
| unknown | 2 of 96 (2%) |
4 of 67 (6%) |
10 of 124 (8%) |
16 of 287 (5.6%) |
|||||
| Histotype ¶ | NOS f | 28 of 96 (29.2%) |
16 of 67 (23.9%) |
31 of 124 (25%) |
75 of 287 (26.1%) |
0.1 ‡ | 0.08 ‡ | 0.2 ‡ | 0.7 ‡ |
| Nodular g | 47 of 96 (49%) |
33 of 67 (49.3%) |
56 of 124 (45.2%) |
136 of 287 (47.5%) |
|||||
| Superficial spreading h | 14 of 96 (14.6%) |
12 of 67 (17.9%) |
13 of 124 (10.5%) |
39 of 287 (13.6%) |
|||||
| Acral i | 0 of 96 (0%) |
1 of 67 (1.5%) |
6 of 124 (4.8%) |
7 of 287 (2.4%) |
|||||
| Others l, m, n, o, p, q, r | 7 of 96 (7.3%) |
4 of 67 (6%) |
18 of 124 (14.5%) |
29 of 287 (10.1%) |
|||||
| Unknown | 0 of 96 (0%) |
1 of 67 (1.5%) |
0 of 124 (0%) |
1 of 287 (0.3%) |
|||||
† Ordinary one-way ANOVA test (the unknown cases were excluded from the analysis). †† Unpaired t-test (the unknown cases were excluded from the analysis). ‡ Chi-square test (the unknown cases were excluded from the analysis). Underlined p highlights statistically significant results by univariate analysis (p < 0.05). § ICD-O code was used to define anatomical tumor localization: a. C44.0; C44.1; C44.2; C44.3; C44.4; b. C44.5; c. C44.6; d. C44.7 and e. C51.0. ¶ SNOMED code was used to define tumor histotypes: f. not specified, g. M87213; h. M87433; i. M87443; l. M87453; m. M87723; n. M87733; o. M87803; p. M87303; q. M87423; r. M87713.